Affinicon has identified its first medical indication within inflammation and produced  the first humanized antibody conjugate drug for anti-inflammatory therapy.

Affinicon has obtained proof of concept in animal models for the unique combination of high efficacy/low side-effects characterising the Affinicon platform by testing its lead drug candicte Cymac-001 in rats and pigs. Macrophage targeting is enabling a substantial dose reduction (factor 50) of dexamethasone to achieve anti-inflammatory efficacy comparable to free dexamethasone.


Affinicon ApS Science Park Aarhus, Aabogade 15, 8200 Aarhus N